

Table S1 Treatments used in first-line and subsequent therapies in the original population (N=499)

Treatments	Value, n [%]
First-line therapy	499 [98]
Oxaliplatin-based doublets	144 [28]
Oxaliplatin-based doublets + anti-VEGF	87 [17]
Irinotecan-based doublets + anti-VEGF	69 [14]
Oxaliplatin-based doublets + anti-EGFR	51 [10]
Irinotecan-based doublets + anti-EGFR	35 [7]
Irinotecan-based doublets	34 [7]
Triplet regimens	21 [4]
Fluoropyrimidine alone + anti-VEGF	20 [4]
Triplet regimens + anti-VEGF	18 [4]
Fluoropyrimidine alone	16 [3]
Irinotecan alone + anti-EGFR	3 [1]
Irinotecan alone	1 [0.2]
Second-line therapy	332 [65]
Irinotecan-based doublets + anti-VEGF	92 [18]
Oxaliplatin-based doublets + anti-VEGF	52 [10]
Irinotecan-based doublets + anti-EGFR	49 [10]
Irinotecan-based doublets	46 [9]
Oxaliplatin-based doublets	31 [6]
Fluoropyrimidine alone + anti-VEGF	18 [4]
Oxaliplatin-based doublets + anti-EGFR	11 [2]
Fluoropyrimidine alone	10 [2]
Regorafenib	9 [2]
Irinotecan alone + anti-EGFR	5 [1]
Triplet regimens	4 [1]
Triplet regimens + anti-VEGF	2 [1]
Anti-EGFR alone	2 [1]
TFD/TPI	1 [0.2]

Table S1 (continued)**Table S1** (continued)

Treatments	Value, n [%]
Third-line therapy	163 [32]
Oxaliplatin-based doublets	25 [5]
Oxaliplatin-based doublets + anti-VEGF	25 [5]
Irinotecan-based doublets + anti-VEGF	24 [5]
Regorafenib	21 [4]
Irinotecan-based doublets + anti-EGFR	14 [3]
Oxaliplatin-based doublets + anti-EGFR	13 [3]
Fluoropyrimidine alone + anti-VEGF	9 [2]
Fluoropyrimidine alone	7 [1]
Irinotecan alone + anti-EGFR	7 [1]
Irinotecan-based doublets	6 [1]
Triplet regimens	3 [0.6]
Anti-EGFR alone	3 [0.6]
TFD/TPI	3 [0.6]
Triplet regimens + anti-VEGF	2 [0.4]
Irinotecan alone	1 [0.2]
Fourth-line therapy	73 [14]
Regorafenib	18 [4]
Irinotecan-based doublets + anti-VEGF	10 [2]
Oxaliplatin-based doublets + anti-EGFR	9 [2]
Oxaliplatin-based doublets	8 [2]
Irinotecan-based doublets + anti-EGFR	5 [1]
Fluoropyrimidine alone	5 [1]
Irinotecan alone + anti-EGFR	5 [1]
Irinotecan-based doublets	4 [0.8]
TFD/TPI	3 [0.6]
Oxaliplatin-based doublets + anti-VEGF	2 [0.4]
Fluoropyrimidine alone + anti-VEGF	2 [0.4]
Anti-EGFR alone	1 [0.2]
Irinotecan alone	1 [0.2]

VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; TFD/TPI, trifluridine/tipiracil.